NOX.ASX: Noxopharms Sofra assets to be presented at global conference

Noxopharms Sofra assets to be presented at global conference

Stock	Noxopharm Ltd (NOX.ASX)
Release Time	20 May 2026, 9:21 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Noxopharm's Sofra assets to be presented at global conference

Key Points

Project with Australian biotechnology leader
Delivery of self-amplifying mRNA vaccines
Demonstrates Sofra versatility and industry interest

Full Summary

Noxopharm Limited (ASX:NOX) is pleased to announce that data from a project involving Noxopharm's Sofra technology platform will be presented by CSL, a global biopharma company, at the Options for the Control of Influenza XIII Conference in Washington DC. The presentation will highlight how Noxopharm's novel oligonucleotides from its Sofra technology platform could be used to improve the delivery of self-amplifying mRNA vaccines. The Sofra platform, developed from a breakthrough discovery in the immune system, targets inflammatory and autoimmune diseases, as well as RNA therapeutics and vaccines, with potential applications across a wide range of immune-related conditions.

Outlook

Noxopharm CEO Dr Olivier Laczka expressed optimism about the Sofra platform's potential in various areas where inflammation plays a role.